230 related articles for article (PubMed ID: 23578679)
1. Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years.
Zivadinov R; Bergsland N; Dolezal O; Hussein S; Seidl Z; Dwyer MG; Vaneckova M; Krasensky J; Potts JA; Kalincik T; Havrdová E; Horáková D
AJNR Am J Neuroradiol; 2013 Oct; 34(10):1931-9. PubMed ID: 23578679
[TBL] [Abstract][Full Text] [Related]
2. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R
J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987
[TBL] [Abstract][Full Text] [Related]
3. Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis.
Bergsland N; Horakova D; Dwyer MG; Dolezal O; Seidl ZK; Vaneckova M; Krasensky J; Havrdova E; Zivadinov R
AJNR Am J Neuroradiol; 2012 Sep; 33(8):1573-8. PubMed ID: 22499842
[TBL] [Abstract][Full Text] [Related]
4. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
5. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
[TBL] [Abstract][Full Text] [Related]
6. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.
Turner B; Lin X; Calmon G; Roberts N; Blumhardt LD
Mult Scler; 2003 Feb; 9(1):21-7. PubMed ID: 12617263
[TBL] [Abstract][Full Text] [Related]
7. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T
Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589
[TBL] [Abstract][Full Text] [Related]
10. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
11. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
[TBL] [Abstract][Full Text] [Related]
12. MRI correlates of disability progression in patients with CIS over 48 months.
Uher T; Horakova D; Bergsland N; Tyblova M; Ramasamy DP; Seidl Z; Vaneckova M; Krasensky J; Havrdova E; Zivadinov R
Neuroimage Clin; 2014; 6():312-9. PubMed ID: 25379444
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
[TBL] [Abstract][Full Text] [Related]
14. Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study.
Bendfeldt K; Egger H; Nichols TE; Loetscher P; Denier N; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Gass A; Kappos L; Radue EW; Borgwardt SJ
Brain Res; 2010 Apr; 1325():174-82. PubMed ID: 20167205
[TBL] [Abstract][Full Text] [Related]
15. Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.
Nourbakhsh B; Azevedo C; Maghzi AH; Spain R; Pelletier D; Waubant E
J Neurol Sci; 2016 Jul; 366():229-233. PubMed ID: 27288812
[TBL] [Abstract][Full Text] [Related]
16. Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study.
Calabrese M; Filippi M; Rovaris M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Grossi P; Barachino L; Rinaldi L; Romualdi C; Perini P; Gallo P
Mult Scler; 2009 Jan; 15(1):36-41. PubMed ID: 18755823
[TBL] [Abstract][Full Text] [Related]
17. Thalamic damage and long-term progression of disability in multiple sclerosis.
Rocca MA; Mesaros S; Pagani E; Sormani MP; Comi G; Filippi M
Radiology; 2010 Nov; 257(2):463-9. PubMed ID: 20724544
[TBL] [Abstract][Full Text] [Related]
18. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
19. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis.
Calabrese M; Agosta F; Rinaldi F; Mattisi I; Grossi P; Favaretto A; Atzori M; Bernardi V; Barachino L; Rinaldi L; Perini P; Gallo P; Filippi M
Arch Neurol; 2009 Sep; 66(9):1144-50. PubMed ID: 19752305
[TBL] [Abstract][Full Text] [Related]
20. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
